Kimia Farma (KAEF), a state-owned pharmaceutical company, is among the most aggressive companies when it comes to expansion. Last year, the company spent Rp1.13 trillion of its cash in investing activities, jumped by nearly 40% from 2017. KAEF reported a strong sales revenue growth of 22% to Rp7.64 trillion last year, while operating profit jumped nearly 43%.To subscribe please click here
